Lombard Medical (OTCMKTS:EVARF – Get Free Report) and Spectral AI (NASDAQ:MDAI – Get Free Report) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, risk, analyst recommendations, profitability, institutional ownership, earnings and valuation.
Profitability
This table compares Lombard Medical and Spectral AI’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Lombard Medical | N/A | N/A | N/A |
| Spectral AI | -85.58% | N/A | -72.97% |
Insider and Institutional Ownership
67.1% of Spectral AI shares are held by institutional investors. 13.7% of Spectral AI shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Earnings & Valuation
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Lombard Medical | N/A | N/A | N/A | N/A | N/A |
| Spectral AI | $19.65 million | 2.82 | -$7.57 million | ($0.53) | -3.28 |
Lombard Medical has higher earnings, but lower revenue than Spectral AI.
Analyst Recommendations
This is a summary of recent ratings and price targets for Lombard Medical and Spectral AI, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Lombard Medical | 0 | 0 | 0 | 0 | 0.00 |
| Spectral AI | 1 | 0 | 1 | 0 | 2.00 |
Spectral AI has a consensus price target of $4.00, indicating a potential upside of 129.89%. Given Spectral AI’s stronger consensus rating and higher possible upside, analysts plainly believe Spectral AI is more favorable than Lombard Medical.
Summary
Spectral AI beats Lombard Medical on 6 of the 8 factors compared between the two stocks.
About Lombard Medical
Lombard Medical, Inc., a medical technology company, develops, manufactures, and markets endovascular stent-grafts for the repair of aortic aneurysms in the United States, the United Kingdom, Germany, Japan, and internationally. The company’s principal product is Aorfix, which is an endovascular stent-graft for the treatment of abdominal aortic aneurysms (AAAs) with angulation at the neck of the aneurysm of up to 90 degrees. Its products also include Altura endovascular stent graft system for the treatment of standard AAA anatomies; Aorflex delivery system for accurate placement of Aorfix in the abdominal aorta; and IntelliFlex LP delivery system that enhances the precision and control of Aorfix deployment and placement. Lombard Medical, Inc. sells its products directly through its direct sales force and distributors to state-or-government-owned hospitals. The company was founded in 2000 and is headquartered in Didcot, the United Kingdom.
About Spectral AI
Spectral AI, Inc., an artificial intelligence (AI) company, focuses on developing predictive medical diagnostics in the United States. The company develops medical diagnostics for faster and accurate treatment decisions in wound care with applications involving patients with burns and diabetic foot ulcers. Its products include DeepView System, a predictive analytics platform integrated with the predictive AI-Burn, which combines AI algorithms and multispectral imaging (MSI) imaging for an assessment of wound healing potential and offers clinicians an objective and immediate assessment of a wound’s healing potential prior to treatment or other medical intervention; and DeepView SnapShot M, a handheld, portable, and wireless diagnostic tool, that provides a potential enhanced and expanded use for the government and emergency care, first responders, and potentially home health care professionals. The company is headquartered in Dallas, Texas.
Receive News & Ratings for Lombard Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lombard Medical and related companies with MarketBeat.com's FREE daily email newsletter.
